beta blockers for heart failure

30
Beta blockers for heart failure Dr. Mahendra Cardiology ,JIPMER

Upload: srcardiologyjipmerpuducherry

Post on 22-Jan-2018

42 views

Category:

Healthcare


4 download

TRANSCRIPT

Page 1: Beta blockers for heart failure

Beta blockers for heart failure

Dr. Mahendra

Cardiology ,JIPMER

Page 2: Beta blockers for heart failure

Most hazardous drug

Most effective therapy

1. Waagstein et al 1975 : Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy2. Waagstein et al 1989 : Long-term beta-blockade in DCM.Effects of short- and long-term metoprolol followed by withdrawal and readministration of metoprolol.3. CIBIS 19944. U.S. Carvedilol Heart FailureStudy Group. 1996 N Engl J Med5. CIBIS II. 1999 Lancet6. MERIT-HF 2000

Β-Blocker status in chronic heart failure

Page 3: Beta blockers for heart failure

Shift in paradigm is because of understanding of CHF

Purely hemodynamic disease

Activation of the deleterious neurohormonal systems and possibly

inflammatory processes are responsible

Page 4: Beta blockers for heart failure

Definitions

I. Heart Failure with Reduced Ejection Fraction (HFrEF) - EF ≤ 40%

II. Heart Failure with Preserved Ejection Fraction (HFpEF) - EF ≥50%

a. HFpEF, Borderline – EF 41% to 49%

b. HFpEF, Improved – EF >40%

Page 5: Beta blockers for heart failure

Classification of Heart FailureACCF/AHA Stages of HF NYHA Functional Classification

A At high risk for HF but without structural heart disease or symptoms of HF.

None

B Structural heart disease but without signs or symptoms of HF.

I No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF.

C Structural heart disease with prior or current symptoms of HF.

I No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF.

II Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF.

III Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms of HF.

IV Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest.

D Refractory HF requiring specialized interventions.

Page 6: Beta blockers for heart failure

STAGE B HF (HFrEF) : Recommendations

In all patients with a recent or remote history of MI or ACS and reduced EF, evidence-based beta blockers should be used to reduce mortality

I IIa IIb III

I IIa IIb IIIBeta blockers should be used in all patients with a reduced EF to prevent symptomatic HF, even if they do not have a history of MI.

Page 7: Beta blockers for heart failure

• Data with beta blockers are less convincing in a population with known CAD, although in 1 trial carvedilol therapy in patients with stage B and low LVEF was associated with a 31% relative risk reduction in adverse long-term outcomes.

Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORNrandomised trial. Lancet. 2001;357:1385–90.

Page 8: Beta blockers for heart failure

Use of 1 of the 3 beta blockers proven to reduce mortality (i.e., bisoprolol, carvedilol, and sustained-release metoprolol succinate)

is recommended for all patients with current or prior symptoms of HFrEF, unless contraindicated, to reduce morbidity and mortality.

STAGE C HF (HFrEF) : Recommendations

I IIaIIb III

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF).

Lancet. 1999;353:2001–7.

Page 9: Beta blockers for heart failure

STAGE C HF (HFpEF) : Recommendations

The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF

I IIa IIb III

Page 10: Beta blockers for heart failure

Maintenance of GDMT During Hospitalization

• Initiation of beta-blocker therapy is recommended after optimization of volume status and successful discontinuation of intravenous diuretics, vasodilators, and inotropic agents.

• Beta-blocker therapy should be initiated at a low dose and only in stable patients.

• Caution should be used when initiating beta blockers in patients who have required inotropes during their hospital course.

I IIa IIb III

Page 11: Beta blockers for heart failure

Is Withdrawal of β-blockers necessary During HF Hospitalization ?

• Continuation of beta blockers for most patients is well tolerated and results in better outcomes

• Withholding of, or reduction in, β-blocker therapy considered only in pts hospitalized after recent initiation or increase in β-blocker therapy or with marked volume overload or marginal/low cardiac output

Metra M, Torp-Pedersen C, Cleland JG, et al. Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure?

Results from COMET. Eur J Heart Fail. 2007;9:901–9

Page 12: Beta blockers for heart failure

β-Blockers in acute HF• Ionotropic agents – Last chance drugs• Abrupt stoppage of β-blockers paradoxical

activation of the SNS , enhanced sensitivity to β-agonists

• More severe the patient is, the more benefit from β-blocker therapy & more risk in stopping chronic β-blocker therapy

• Hospitalization for acute HF: in-hospital mortality, short-term mortality, and combined mortality and hospitalization are lower when β-blockers are maintainedPrins et al .Effects of beta-blocker withdrawal in

acute decompensated heart failure: a systematic review and meta-analysis.JACC 2015

Page 13: Beta blockers for heart failure

Doses of Beta blockers commonly used for HFrEF

Drug Initial Daily Dose(s) Maximum Doses(s) Mean Doses Achieved in Clinical Trials

Beta Blockers

Bisoprolol 1.25 mg once 10 mg once 8.6 mg/d (118)

Carvedilol 3.125 mg twice 50 mg twice 37 mg/d (446)

Carvedilol CR 10 mg once 80 mg once ---------

Metoprolol succinate extended release (metoprolol CR/XL)

12.5 to 25 mg once 200 mg once 159 mg/d (447)

Page 14: Beta blockers for heart failure

• Current data do not support a difference between selective and nonselective β-blockers.

• Of note, the lipophilic β-blockers may be more beneficial than hydrophilic β-blockers in reducing the risk of sudden death.

Page 15: Beta blockers for heart failure
Page 16: Beta blockers for heart failure

Nebivolol

• Beta-1 selective blocker nebivolol demonstrated a modest reduction in the primary endpoint of all-cause mortality or cardiovascular hospitalization

• But did not affect mortality alone in an elderly population that included patients with HFpEF

• 1.25 mg o.d. to target dose 10 mg o.d.

SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure).

J Am Coll Cardiol. 2009;53:2150–8.

Page 17: Beta blockers for heart failure

Benefits of beta blockers

Long-term treatment with beta blockers can

•Lessen the symptoms of HF

•Improve pt’s clinical status and

•Enhance pt’s overall sense of well-being

•Reduce the risk of death and the combined risk of death or hospitalization

Benefits irrespective of CAD,DM,Sex and race

MDC trial, CIBIS study, PRECISE trial, MERIT-HF

Page 18: Beta blockers for heart failure

Beta blockers for Stage C HFrEF: Magnitude of Benefit Demonstrated in RCTs

GDMTRR Reduction in Mortality

NNT for Mortality Reduction

(Standardized to 36 mo)

RR Reductionin HF

Hospitalizations

ACE inhibitor or ARB

17% 26 31%

Beta blocker 34% 9 41%

Aldosterone antagonist

30% 6 35%

Hydralazine/nitrate 43% 7 33%

Page 19: Beta blockers for heart failure
Page 20: Beta blockers for heart failure

Greater improvement of symptoms and clinical status (NYHA class and overall well-being) in pts with moderate to severe symptoms than in those with mild symptoms

Page 21: Beta blockers for heart failure

Beta Blockers: Initiation and Maintenance

• Initiated at very low doses• Gradual increments in dose if lower doses have been well

tolerated• Vital signs and symptoms – monitored closely• 85% of pts able to tolerate and achieve max planned trial

dose with this approach

• Can be safely started before discharge even in patients hospitalized for HF

• Long-term treatment should be maintained, even if symptoms do not improve

Page 22: Beta blockers for heart failure

Start slowly, but start

JACC. 2004;43:1534

Page 23: Beta blockers for heart failure

Caution• In pts with a current or recent history of fluid

retention, beta blockers should not be prescribed without diuretics

• Beta blockers may be considered in patients who have reactive airway disease or asymptomatic bradycardia but should be used cautiously in patients with persistent symptoms of either condition

• Abrupt withdrawal of treatment with a beta blocker can lead to clinical deterioration and should be avoided

Page 24: Beta blockers for heart failure

Risks of beta blockers

1) Fluid retention and worsening HF

2) Bradycardia or heart block

3) Hypotension

4) Fatigue

Page 25: Beta blockers for heart failure

AF and HF

• For pts who develop HF as a result of AF, a rhythm control strategy should be pursued

• In pts with HF who develop AF, a rhythm-control strategy has not been shown to be superior to a rate-control strategy

• β-blockers are the preferred agents for achieving rate control

Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–77

Page 26: Beta blockers for heart failure

Major clinical trials of therapeutic interventions in pts with HFrEF

Page 27: Beta blockers for heart failure
Page 28: Beta blockers for heart failure

META-ANALYSIS

Of 15 smaller trials plus the MDC, CIBIS and carvedilol trials included 3,023 patients.

β-blockers

1. Reduced all-cause mortality by 32 % (P = 0.003)

2. Reduced the combined risk of death or hospitalization because of heart failure by 37 % (P < 0.001)

3. Increased the EF by 29% (P < 10-9 )

Page 29: Beta blockers for heart failure
Page 30: Beta blockers for heart failure

Conclusion

• β-B are currently the cornerstone in HF therapy

• Bisoprolol,Carvedilol and SR metoprolol succinate – currently approved β-B for HF

• Uptitrating to max dose achieved in clinical trials necessary to achieve max benefit

• Withholding β-B not necessary in HF hospitalisation